An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells

BACKGROUND: Acquired drug resistance to irinotecan is one of the significant obstacles in the treatment of advanced gastric cancer. This study was performed to clarify the effect of epidermal growth factor receptor (EGFR) inhibitors in combination with SN38, an active metabolite of irinotecan, on th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yashiro, M, Qiu, H, Hasegawa, T, Zhang, X, Matsuzaki, T, Hirakawa, K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2011
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3242520/
https://ncbi.nlm.nih.gov/pubmed/21997136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.397
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak